Piper Sandler Reiterates Overweight Rating on aTyr Pharma (ATYR)

October 21, 2024 7:35 AM EDT Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $20.00 price target on aTyr Pharma (NASDAQ: ATYR).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login